Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CACNA2D1 | P54289 | 8/20 | 0.61 |
| ▸ | CACNB1 | Q02641 | 8/20 | 0.61 |
| ▸ | CACNA1B | Q00975 | 7/20 | 0.61 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.61 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19231623 | 0.83 | SMN1; SMN2 (0.74) | NPSR1MAPTALOX12SMN1; SMN2HTT | |
| SCHEMBL7665618 | 0.81 | NPC1 (0.78) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL31329301 | 0.80 | HTT (1.00) | NPSR1MAPTALOX12SMN1; SMN2HTT | |
| SCHEMBL15134824 | 0.79 | SMN1; SMN2 (0.80) | NPSR1MAPTALOX12SMN1; SMN2HTT | |
| SCHEMBL1446803 | 0.78 | NPC1 (0.85) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL1446552 | 0.78 | NPC1 (0.85) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL15337749 | 0.77 | SMN1; SMN2 (0.76) | NPSR1MAPTALOX12SMN1; SMN2HTT | |
| SCHEMBL655032 | 0.77 | HTT (0.78) | NPSR1MAPTALOX12SMN1; SMN2HTT | |
| SCHEMBL15703692 | 0.77 | NPC1 (0.71) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G | |
| SCHEMBL1446717 | 0.77 | NPC1 (0.71) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | claimed |
| EP-1976841-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-10-08 | — | — | EP | claimed |
| WO-2007071035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-06-28 | — | — | WO | claimed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | RYR2, CACNA1E, RYR1 | NPSR1 175/4885MAPT 3601/4885ALOX12 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.